NCT02569502View on ClinicalTrials.gov

A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
HIV Infections
Interventions
DRUG

enfuvirtide

Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.

Trial Locations (1)

1431

Sofia

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02569502 - A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection | Biotech Hunter | Biotech Hunter